Commentary
Video
Dr Poh on the Preliminary Efficacy of Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma
Author(s):
Christina Poh, MD, discusses results from the phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.
Christina Poh, MD, assistant professor, University of Washington, Fred Hutchinson Cancer Center, discusses results from the phase 3 inMIND study (NCT04680052) of tafasitamab (Monjuvi) plus lenalidomide (Revlimid) and rituximab (Rituxan) for relapsed/refractory follicular lymphoma. Results from the study were presented at the 2024 ASH Annual Meeting.
Related Videos
Related Content
